8 Site Selection and Feasibility Companies for Clinical Trials in 2026

A feasibility assessment provider helps a sponsor answer a deceptively hard question before a trial ever starts: can this protocol's eligibility criteria actually be met, and if so, which sites and patient populations give it the best shot at enrolling on time? This kind of clinical trial site feasibility vendor ranges from data-driven platforms that mine real-world patient records and historical site performance to identify strong-fit sites, to consultative teams that combine investigator databases with direct outreach to assess a site's true capacity before a study is designed around it.

The site selection and feasibility companies below are listed in no particular order. Between them, these companies and providers cover real-world-data-driven feasibility platforms, AI-powered protocol and site analysis, marketplace models that let sites self-select trials, and therapeutic-area-specific feasibility expertise.

BEKHealth

BEKHealth's AI-powered patient-matching platform draws on records from more than 43 million patients across 1,600 partner clinical sites to help sponsors streamline both site selection and patient recruitment, extracting structured and unstructured data directly from electronic medical records. Founded in Kent, Washington in 2020, the company built a proprietary medical ontology from more than 400 medical libraries mapped against 70,000 clinical trial protocols, letting its platform capture roughly three times more trial eligibility criteria than traditional keyword-based systems. BEKHealth's approach to site selection starts from where eligible patients already exist in the healthcare system, rather than relying on a site's self-reported enrollment estimates. The company positions its EMR-based data platform as a way to identify protocol-eligible candidates and appropriate research sites more accurately than manual feasibility questionnaires alone.

Confidence Pharma

Confidence Pharmaceutical Research builds its feasibility and site selection process around a database of thousands of clinical investigators and biomedical research experts worldwide, using demographic and infrastructure data alongside historical site performance metrics to identify strong-fit sites for a given study. The company was founded in 2014 by Dr. Sergei Varshavsky and Dr. Efim Kelman, who previously built Evidence Clinical and Pharmaceutical Research, one of the first CROs in Eastern Europe, growing it to more than 350 employees across five countries before its acquisition by a global CRO. Headquartered in Redwood City, California, Confidence maintains standardized documentation it calls Confidence Quality Management Documentation (CQMD) to keep site feasibility and other operations consistent across studies and therapeutic areas. The company's feasibility team uses its proprietary tools to identify key opinion leaders across therapeutic areas and propose an optimal mix of sites for both rare disease studies and large-scale global outcome trials.

Frenova Renal Research

Frenova Renal Research is the world's only Phase I–IV contract clinical development services provider dedicated exclusively to renal research, drawing on parent company Fresenius Medical Care North America's network of dialysis clinics and kidney care practices to assess protocol feasibility and identify sites. The company, formerly known as the Clinical Studies Group at Fresenius, was rebranded as Frenova in 2018 and manages a network of more than 450 principal investigators across more than 260 research sites representing 160 medical practices and nearly 700 dialysis clinics. Frenova provides access to a patient population of more than 390,000 people with chronic kidney disease and 183,000 people with end-stage renal disease, giving sponsors a feasibility and recruitment pool built on decades of real-world dialysis treatment data. The company has reported reducing the time from clinical trial agreement to first-patient-first-visit by more than 80 percent among the sites it manages between 2016 and 2018.

Inato

Inato operates a clinical trial marketplace that flips traditional site selection, letting more than 5,500 community-based research sites review upcoming trial opportunities and self-select the studies that best fit their patient populations, rather than sponsors unilaterally choosing sites. Founded in 2016 by CEO Kourosh Davarpanah and headquartered in Paris, the company built its platform around a historical performance dataset spanning more than 1,500 studies, 17,000 sites, and 700,000 patients across more than 80 countries, which it says can reduce the number of sites needed for a study by nearly 30 percent. Inato began as a dedicated feasibility platform before expanding into a full clinical trials marketplace, and the company reports its approach has increased sites' odds of selection by an average of 94 percent by giving them a way to demonstrate their specific strengths to sponsors. In 2024, Inato was recognized as one of Fast Company's most innovative biotech companies for its work bringing diverse patient populations into trials for sponsors including Moderna and Sanofi.

Neuroute

Neuroute runs an AI-powered clinical trial platform that analyzes historical protocols against outcomes data to support feasibility assessment and study design, extending into site selection, principal investigator and KOL collaboration management, and enrollment modeling. The company was founded by CEO Livia Lifes, whose background in neuroscience and neural computation led her to build what began as a research project before becoming Neuroute, and the company was named one of Sifted's Top 20 European Cancer Tech Startups. Neuroute is backed by PharmStars, an accelerator program supported by AstraZeneca, Pfizer, Novo Nordisk, Boehringer Ingelheim, Takeda, Roche, and Eli Lilly. The platform draws on a database the company describes as spanning more than 700,000 studies and 1.5 billion publications to generate tailored clinical trial designs and operational plans for sponsors.

NorthWest EHealth (NWEH)

NorthWest EHealth (NWEH) built FARSITE, a secure platform that enables rapid clinical trial feasibility assessment across a representative patient population while preserving individual anonymity, using inclusion and exclusion criteria to pinpoint likely trial participants without transferring underlying patient data between organizations. In November 2024, the Manchester-based company announced a pilot combining FARSITE with the UK's Clinical Practice Research Datalink (CPRD), giving sponsors secure access to more than 18 million anonymized patient records for feasibility and find-and-refer services at a scale the company says had not previously been possible in the UK. CEO Jonathan Wogel has positioned the CPRD partnership as a way to reposition the UK as a global leader in clinical research, particularly for reaching more diverse and historically underserved patient populations. NWEH has also partnered with AbbVie's UK business, using FARSITE's primary care data cohort-finding capabilities to support real-world evidence generation across Greater Manchester's diverse population base.

Pharpoint Research

PharPoint Research takes what it calls a site-agnostic approach to site feasibility, working to identify and select the best-fit site partner for a given study's specific requirements rather than steering sponsors toward owned research units that may not be the ideal match. Founded in 2007 and based in Durham, North Carolina's Research Triangle Park, the company has supported more than 1,000 clinical trials and won the Triangle Business Journal's Most Innovative CRO award, alongside a finalist nod for the Scrip Awards' Best Specialist CRO category in 2019. PharPoint's feasibility process is led by a dedicated feasibility manager role within its clinical operations team, and the company maintains long-term relationships with specialized patient recruitment and retention vendors it can bring into a study when added expertise would help. The company also offers a database-lock timeline of just five days after a trial's last patient, last visit and final source data verification, positioning fast feasibility and site selection as part of a broader speed-focused operating model.

TriNetX

TriNetX operates a global health research network that combines real-time access to longitudinal clinical data from more than 137 healthcare organizations across 17 countries with analytics tools built to optimize protocol design, feasibility, and site selection. Incorporated in 2013 and headquartered in Cambridge, Massachusetts, the company's TriNetX LIVE platform lets sponsors assess study eligibility criteria against real-world data on millions of current patients before moving into site engagement, and its Single Study Service (S3) offers smaller biotech and pharma companies turnkey feasibility analyses on a per-study basis. In one published case, Sanofi UK used TriNetX to optimize its protocol feasibility process and identify Royal Berkshire NHS Foundation Trust as a strong-fit site through the platform. TriNetX reports its patient-centric approach to site identification, which starts from where target patient populations already receive treatment rather than from a fixed list of known sites, has helped reduce time to site identification by up to 50 percent.

Explore the full Feasibility & Site Selection landscape

The companies above represent a portion of a much larger field.

Diligent's platform includes over 335 Feasibility & Site Selection Vendors, with Vendor qualification data available on demand. Talk to our team about accessing qualification data for this category.

This article is intended as an informational overview of vendors operating in this space. Inclusion on this list does not constitute an endorsement, recommendation, or qualification by Diligent.